Second Sight Announces Professor Stanislao Rizzo Has Completed His 30th Implant of the Argus II Retinal Prosthesis
February 21 2017 - 8:00AM
Business Wire
Second Sight Medical Products, Inc. (Nasdaq:EYES),
("Second Sight" or "the Company"), a developer, manufacturer and
marketer of implantable visual prosthetics to provide some useful
vision to blind patients, today announced that Professor Stanislao
Rizzo (Professor Rizzo) has completed his 30th implant of the
Argus® II Retinal Prosthesis (Argus II) at the Azienda Ospedaliero
Universitaria Careggi located in Florence, Italy.
Will McGuire, President and CEO of Second Sight Medical
Products, stated, “This represents an exciting milestone in Italy
and an important achievement for Second Sight as we continue to
advance our goal of making the Argus II available to patients with
Retinitis Pigmentosa (RP). Professor Rizzo sets a standard in both
quality of outcomes and volume, which serves as a goal for our
centers of excellence all around the world.”
The 30th surgery, out of more than 220 Argus II implants
worldwide, was performed by Professor Rizzo on February 9, 2017 at
Azienda Ospedaliero Universitaria Careggi, one of three centers in
Italy capable of performing the surgical procedure and
post-operative rehabilitation required for Argus II patients.
Professor Rizzo has implanted the Argus II at centers in Florence
and Pisa, Italy since the system became available in 2011; he has
trained surgeons at several international centers.
Professor Rizzo commented, “Over the last five years, I realized
not only that the system is safe, but above all, I was able to
personally see that its validity and benefits can be maintained for
a long time, and that the satisfaction for patients who recover
vision is truly rewarding.”
In Europe, Argus II is indicated for blind people suffering from
advanced outer retinal degenerative diseases such as RP. RP is an
inherited disease that often results in nearly complete blindness,
affecting an estimated 167,000 Europeans.
About the Argus II Retinal Prosthesis System
Second Sight's Argus II System provides electrical stimulation
that bypasses the defunct retinal cells and stimulates remaining
viable cells inducing visual perception in individuals with severe
to profound Retinitis Pigmentosa. The Argus II works by converting
images captured by a miniature video camera mounted on the
patient's glasses into a series of small electrical pulses, which
are transmitted wirelessly to an array of electrodes implanted on
the surface of the retina. These pulses are intended to stimulate
the retina's remaining cells, resulting in the perception of
patterns of light in the brain. The patient then learns to
interpret these visual patterns, thereby regaining some visual
function. The Argus II is the first artificial retina to receive
widespread approval, and is offered at approved centers in Canada,
France, Germany, Italy, Saudi Arabia, Spain, Turkey, United
Kingdom, and the U.S.
About Second Sight
Second Sight's mission is to develop, manufacture and market
innovative implantable visual prosthetics to enable blind
individuals to achieve greater independence. Second Sight has
developed and manufactures the Argus II Retinal Prosthesis System.
Second Sight is currently underway in a trial to test the safety
and utility of the Argus II in individuals with Dry Age-Related
Macular Degeneration. Second Sight is also developing the
Orion™ I Visual Cortical Prosthesis to restore some vision to
individuals who are blind due to causes other than preventable or
treatable conditions. U.S. Headquarters are in Sylmar, California,
and European Headquarters are in Lausanne, Switzerland. For more
information, visit www.secondsight.com.
Safe Harbor
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange and Exchange
Act of 1934, as amended, which are intended to be covered by the
"safe harbor" created by those sections. All statements in this
release that are not based on historical fact are "forward looking
statements." These statements may be identified by words such as
"estimates," "anticipates," "projects," "plans," or "planned,"
"seeks," "may," "will," "expects," "intends," "believes," "should"
and similar expressions or the negative versions thereof and which
also may be identified by their context. All statements that
address operating performance or events or developments that Second
Sight expects or anticipates will occur in the future are
forward-looking statements. While management has based any forward
looking statements included in this release on its current
expectations, the information on which such expectations were based
may change. Forward-looking statements involve inherent risks and
uncertainties which could cause actual results to differ materially
from those in the forward-looking statements, as a result of
various factors including those risks and uncertainties described
in the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our
Annual Report on Form 10-K as filed on March 11, 2016, as
amended on August 8, 2016, and our other reports filed from
time to time with the Securities and Exchange Commission. We
urge you to consider those risks and uncertainties in evaluating
our forward-looking statements. We caution readers not to place
undue reliance upon any such forward-looking statements, which
speak only as of the date made. Except as otherwise required by the
federal securities laws, we disclaim any obligation or undertaking
to publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170221005657/en/
Second Sight Medical Products, Inc.Investor
Relations:Institutional InvestorsIn-Site Communications, Inc.Lisa
Wilson, 212-452-2793Presidentlwilson@insitecony.comorIndividual
InvestorsMZ North AmericaGreg Falesnik, 949-385-6449Managing
Directorgreg.falesnik@mzgroup.us
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024